With a reputation as a smart and pragmatic problem-solver, Yoon is a trusted legal advisor and leader in the life sciences industry. A Principal in the firm’s life sciences litigation practice, Yoon counsels global pharmaceutical innovators and research institutions on all aspects of patent rights, including those pertaining to small molecules and biologics inventions. Yoon’s commitment to her clients’ success is clear in her work. She has significant experience as lead counsel, representing pharmaceutical clients before the Federal Court and Federal Court of Appeal in complex patent litigation, including under the Patented Medicines (Notice of Compliance) Regulations. Yoon and her team successfully appealed to the Supreme Court of Canada on the controversial question of “promised utility.” The Supreme Court of Canada, in an important and highly anticipated decision, AstraZeneca Canada Inc v. Apotex Inc, 2017 SCC 36, rejected the “promise doctrine” and clarified the requirement for patent “utility” in Canada. The unanimous decision represents an important victory for innovators seeking protection in Canada.
